{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:28:44Z","timestamp":1793831324908,"version":"4.6.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s12325-025-03255-y","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T03:27:58Z","timestamp":1750303678000},"page":"3993-4012","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A Randomized Phase I Trial Evaluating Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Eclitasertib, a RIPK1 Inhibitor, in Healthy Participants"],"prefix":"10.1007","volume":"42","author":[{"given":"Christine","family":"Farenc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Francois","family":"Clot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Badalamenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie J.","family":"Kruger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Pomponio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tillmann","family":"Krahnke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heribert","family":"Staudinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,19]]},"reference":[{"key":"3255_CR1","doi-asserted-by":"publisher","first-page":"9714","DOI":"10.1073\/pnas.1901179116","volume":"116","author":"A Degterev","year":"2019","unstructured":"Degterev A, Ofengeim D, Yuan J. Targeting RIPK1 for the treatment of human diseases. Proc Natl Acad Sci USA. 2019;116:9714\u201322.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3255_CR2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.tibs.2018.11.002","volume":"44","author":"EJ Petrie","year":"2019","unstructured":"Petrie EJ, Czabotar PE, Murphy JM. The structural basis of necroptotic cell death signaling. Trends Biochem Sci. 2019;44:53\u201363.","journal-title":"Trends Biochem Sci"},{"key":"3255_CR3","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.semcdb.2020.06.013","volume":"109","author":"Z Liu","year":"2021","unstructured":"Liu Z, Chan FK. Regulatory mechanisms of RIPK1 in cell death and inflammation. Semin Cell Dev Biol. 2021;109:70\u20135.","journal-title":"Semin Cell Dev Biol"},{"issue":"3309\u201319","key":"3255_CR4","volume":"28","author":"EJ Petrie","year":"2019","unstructured":"Petrie EJ, Sandow JJ, Lehmann WIL, et al. Viral MLKL homologs subvert necroptotic cell death by sequestering cellular RIPK3. Cell Rep. 2019;28(3309\u201319): e5.","journal-title":"Cell Rep"},{"key":"3255_CR5","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41573-020-0071-y","volume":"19","author":"L Mifflin","year":"2020","unstructured":"Mifflin L, Ofengeim D, Yuan J. Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target. Nat Rev Drug Discov. 2020;19:553\u201371.","journal-title":"Nat Rev Drug Discov"},{"key":"3255_CR6","doi-asserted-by":"publisher","first-page":"14971","DOI":"10.1021\/acs.jmedchem.2c01518","volume":"65","author":"K Shi","year":"2022","unstructured":"Shi K, Zhang J, Zhou E, Wang J, Wang Y. Small-molecule receptor-interacting protein 1 (RIP1) inhibitors as therapeutic agents for multifaceted diseases: current medicinal chemistry insights and emerging opportunities. J Med Chem. 2022;65:14971\u201399.","journal-title":"J Med Chem"},{"key":"3255_CR7","doi-asserted-by":"publisher","first-page":"1159743","DOI":"10.3389\/fimmu.2023.1159743","volume":"14","author":"W Li","year":"2023","unstructured":"Li W, Yuan J. Targeting RIPK1 kinase for modulating inflammation in human diseases. Front Immunol. 2023;14:1159743.","journal-title":"Front Immunol"},{"key":"3255_CR8","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1038\/s41422-021-00578-7","volume":"31","author":"G Xu","year":"2021","unstructured":"Xu G, Li Y, Zhang S, et al. SARS-CoV-2 promotes RIPK1 activation to facilitate viral propagation. Cell Res. 2021;31:1230\u201343.","journal-title":"Cell Res"},{"key":"3255_CR9","doi-asserted-by":"publisher","first-page":"1041315","DOI":"10.3389\/fimmu.2022.1041315","volume":"13","author":"M Sultan","year":"2022","unstructured":"Sultan M, Adawi M, Kol N, et al. RIPK1 mutations causing infantile-onset IBD with inflammatory and fistulizing features. Front Immunol. 2022;13:1041315.","journal-title":"Front Immunol"},{"key":"3255_CR10","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.3389\/fimmu.2019.01094","volume":"10","author":"R Garcia-Carbonell","year":"2019","unstructured":"Garcia-Carbonell R, Yao SJ, Das S, Guma M. Dysregulation of intestinal epithelial cell RIPK pathways promotes chronic inflammation in the IBD Gut. Front Immunol. 2019;10:1094.","journal-title":"Front Immunol"},{"key":"3255_CR11","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1073\/pnas.1813582116","volume":"116","author":"Y Li","year":"2019","unstructured":"Li Y, Fuhrer M, Bahrami E, et al. Human RIPK1 deficiency causes combined immunodeficiency and inflammatory bowel diseases. Proc Natl Acad Sci USA. 2019;116:970\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3255_CR12","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1126\/science.aar2641","volume":"361","author":"D Cuchet-Lourenco","year":"2018","unstructured":"Cuchet-Lourenco D, Eletto D, Wu C, et al. Biallelic RIPK1 mutations in humans cause severe immunodeficiency, arthritis, and intestinal inflammation. Science. 2018;361:810\u20133.","journal-title":"Science"},{"key":"3255_CR13","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/cpt.1615","volume":"107","author":"HW Grievink","year":"2020","unstructured":"Grievink HW, Heuberger J, Huang F, et al. DNL104, a centrally penetrant RIPK1 inhibitor, inhibits RIP1 kinase phosphorylation in a randomized phase I ascending dose study in healthy volunteers. Clin Pharmacol Ther. 2020;107:406\u201314.","journal-title":"Clin Pharmacol Ther"},{"key":"3255_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13690","volume":"17","author":"A Hincelin-Mery","year":"2024","unstructured":"Hincelin-Mery A, Nicolas X, Cantalloube C, et al. Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants. Clin Transl Sci. 2024;17: e13690.","journal-title":"Clin Transl Sci"},{"key":"3255_CR15","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1111\/cts.13317","volume":"15","author":"M Vissers","year":"2022","unstructured":"Vissers M, Heuberger J, Groeneveld GJ, et al. Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: randomized, placebo-controlled, double-blind phase I\/Ib studies in healthy subjects and patients. Clin Transl Sci. 2022;15:2010\u201323.","journal-title":"Clin Transl Sci"},{"key":"3255_CR16","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1177\/009286159502900324","volume":"29","author":"K Gough","year":"1995","unstructured":"Gough K, Hutchison M, Keene O, et al. Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry\/pharmacokinetics UK Joint Working Party. Drug Inf J. 1995;29:1039\u201348.","journal-title":"Drug Inf J"},{"key":"3255_CR17","first-page":"26","volume":"3","author":"MS Ahn","year":"2013","unstructured":"Ahn MS. Current concepts of premature ventricular contractions. J Lifestyle Med. 2013;3:26\u201333.","journal-title":"J Lifestyle Med"},{"key":"3255_CR18","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1111\/cts.13607","volume":"16","author":"NS Jones","year":"2023","unstructured":"Jones NS, Kshirsagar S, Mohanan V, et al. A phase I, randomized, ascending-dose study to assess safety, pharmacokinetics, and activity of GDC-8264, a RIP1 inhibitor, in healthy volunteers. Clin Transl Sci. 2023;16:1997\u20132009.","journal-title":"Clin Transl Sci"},{"key":"3255_CR19","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1111\/cts.13580","volume":"16","author":"J Lickliter","year":"2023","unstructured":"Lickliter J, Wang S, Zhang W, et al. A phase I randomized, double-blinded, placebo-controlled study assessing the safety and pharmacokinetics of RIPK1 inhibitor GFH312 in healthy subjects. Clin Transl Sci. 2023;16:1691\u2013703.","journal-title":"Clin Transl Sci"},{"key":"3255_CR20","unstructured":"Dose-finding Study of SAR443122 in adult participants with ulcerative colitis (NCT05588843). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05588843?term=sar443122&draw=2&rank=3. Accessed 12 June 2023"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03255-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03255-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03255-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T20:31:10Z","timestamp":1757190670000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03255-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,19]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["3255"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03255-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,19]]},"assertion":[{"value":"6 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors (Christine Farenc, Pierre-Francois Clot, Salvatore Badalamenti, Annie J. Kruger, Robert J. Pomponio, Tillmann Krahnke, Heribert Staudinger, Yong Lin) were employees of Sanofi at the time this study was conducted and may hold shares\/stocks in the company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study protocol was approved by independent ethics committee (\n                      The Medical Research Ethics Committee of the \u2018Stichting Beoordeling Ethiek Biomedisch Onderzoek\u2019 [Foundation of Ethics in Biomedical Research], Assen, The Netherlands\n                      ) and\/or institutional review boards and was conducted in accordance with the Declaration of Helsinki and the International Council for Harmonization guidelines for Good Clinical Practice. The participants were informed of the risks and benefits of the trial, and that they could withdraw from the trial at any time for any reason. Written informed consent was obtained from all the participants before any study-related interventions were administered.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}